Geoffrey Michael Grande Solid Biosciences Inc.

If you’re looking for Geoffrey Michael Grande Solid Biosciences Inc., you’ve come to the right place. Use the relevant links provided below to gain direct access.

Geoffrey M. Grande, Director-Investor Relations at …

https://relationshipscience.com/person/geoffrey-m-grande-165438421

Geoffrey M. Grande is Director-Investor Relations of Merrimack Pharmaceuticals, Inc. and Investor Relations Contact at Solid Biosciences, Inc.

Solid Biosciences Announces Preliminary SGT-001 Data and

https://www.globenewswire.com/news-release/2019/02/07/1712000/0/en/Solid-Biosciences-Announces-Preliminary-SGT-001-Data-and-Intention-to-Dose-Escalate-in-IGNITE-DMD-Clinical-Trial-for-Duchenne-Muscular-Dystrophy.html

07/02/2019 · Solid Biosciences Announces Preliminary SGT-001 Data and Intention to Dose Escalate in IGNITE DMD Clinical Trial for Duchenne Muscular Dystrophy. … Geoffrey M. Grande, CFA

Insights & News • Solid Biosciences

https://www.solidbio.com/about/media/news

27/03/2020 · Solid Biosciences Inc., is a Cambridge, MA-based life sciences company focused on developing transformative treatments to improve the lives of patients with Duchenne muscular dystrophy. The characterization of the discovery and development efforts on this website, as well as the expectations associated with them, are reflective of the current …

Our Leadership – AVROBIO

https://www.avrobio.com/about-avrobio/our-leadership

Our leadership team moves in one direction: forward. Our focus unites the world-class experts we have brought together across cell and gene therapy, rare disease, clinical development and manufacturing. We share a passion for science, a commitment to teamwork and, above all, dedication to families and individuals living with genetic diseases.

Solid Biosciences Reports First Quarter 2019 Financial …

https://finance.yahoo.com/news/solid-biosciences-reports-first-quarter-201000970.html

13/05/2019 · Michael Kelley. Michael Kelley. Myles Udland. … Solid Biosciences Inc. Condensed Consolidated Balance Sheets … Geoffrey M. Grande, CFA +1 617-766-3398

Solid Biosciences Announces Upcoming Preclinical Data …

https://www.solidbio.com/about/media/press-releases/solid-biosciences-announces-upcoming-preclinical-data-presentations-at-the-american-society-of-gene-and-cell-therapy-annual-meeting

02/05/2019 · CAMBRIDGE, Mass., April 15, 2019 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (NASDAQ:SLDB) today announced that preclinical data from its gene therapy program for Duchenne muscular dystrophy (DMD) will be presented at the 22 nd Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) held April 29-May 2, 2019 in Washington, D.C.. Oral Presentations:

Solid Biosciences Reports Fourth Quarter and Fiscal Year

https://www.globenewswire.com/news-release/2019/03/13/1752412/0/en/Solid-Biosciences-Reports-Fourth-Quarter-and-Fiscal-Year-2018-Financial-Results-and-Provides-Business-Update.html

13/03/2019 · Solid Biosciences Inc. Consolidated Statements of Operations (unaudited, in thousands, except share and per share data) … Geoffrey M. Grande, CFA +1 617-766-3398

Solid Biosciences Announces Preliminary SGT-001 Data and …

https://investors.solidbio.com/news-releases/news-release-details/solid-biosciences-announces-preliminary-sgt-001-data-and

07/02/2019 · Solid Biosciences Inc., is a Cambridge, MA-based life science company committed to solving Duchenne muscular dystrophy and improving the lives of patients. Solid is currently developing gene therapies, disease modifying therapies and assistive devices, all targeting the many facets of …

Our Leadership – AVROBIO

https://www.avrobio.com/about-avrobio/our-leadership

Our leadership team moves in one direction: forward. Our focus unites the world-class experts we have brought together across cell and gene therapy, rare disease, clinical development and manufacturing. We share a passion for science, a commitment to teamwork and, above all, dedication to families and individuals living with genetic diseases.

Tessera Therapeutics | Team

https://www.tesseratherapeutics.com/team

Jake is Co-Founder and Chief Scientific Officer of Tessera Therapeutics, as well as a Principal at Flagship Pioneering. Jake joined Flagship Pioneering in 2015 and works as part of a venture-creation team, founding and growing companies based on new biotechnology. At Flagship, Jake launched Kaleido Biosciences and co-founded Sana Biotechnology.

 

This Is How You Can Easily Get To The Geoffrey Michael Grande Solid Biosciences Inc. And take advantage of the features that Geoffrey Michael Grande Solid Biosciences Inc. page provides on their portal. Please let us know if you have any trouble with the process or anything else in the comments section.

Leave a Comment